Another single-arm prospective trial of osimertinib plus bevacizumab in 14 patients with leptomeningeal metastasis (LM) from EGFR mutation showed an LM ORR of 50%, median PFS of 9.3 months, median OS of 12.6 months, and one-year survival rate of 35.7% (Lu et al., 2021). This evidence concerns the gene EGFR and lymphangioma.